This article was originally published on The limbic Subcutaneous daratumumab with pomalidomide and dexamethasone (D-Pd) is an effective and convenient treatment for patients with relapsed or refractory multiple myeloma who have received at least one line of therapy, including lenalidomide and a proteasome inhibitor. Speaking at the 62nd ASH Annual Meeting, Professor Meletios Dimopoulos presented...Continue Reading

Originally published on Health Industry Hub The management of New Zealand’s most common blood cancer, myeloma, is falling behind the rest of the world, putting lives at unnecessary risk of this incurable but treatable disease. This is a concerning finding of the Burden of Multiple Myeloma economics report released today by Myeloma New Zealand, who...Continue Reading

This story was originally published on RNZ  An advocate group is warning that New Zealanders are dying from a common blood cancer because they’ve been denied access to medicines. The Burden of Multiple Myeloma economics report, released by Myeloma New Zealand today, stated about 2500 people in New Zealand were living with myeloma, which affects plasma cells typically...Continue Reading

The management of New Zealand’s most common blood cancer, myeloma, is falling behind the rest of the world, putting lives at unnecessary risk of this incurable but treatable disease. This is a concerning finding of the Burden of Multiple Myeloma economics report released today by Myeloma New Zealand, who are calling for improved access to...Continue Reading

This story was originally published on the NZ Herald Kiwis diagnosed with the country’s most common form of blood cancer are being put at unnecessary risk because they are not getting access to the best treatment options available, a support group warns. Myeloma New Zealand chief executive Dr Ken Romeril, prompted by a new report...Continue Reading